PLUS1
34.10
-1.07 (-3.04%)
-1.07 (-3.04%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| REGENXBIO Inc | RGNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -1.07 | -3.04% | 34.10 | 11:22:04 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 34.95 | 33.82 | 35.16 | 35.17 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 34.02 | 34.13 | 0.11 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,084 | 77,595 | $ 34.42 | $ 2,670,994 | 636,483 | 25.925 - 50.26 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:22:04 | 100 | $ 34.10 | USD |
REGENXBIO Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.44B | 42.31M | 28.51M | $ 35.23M | $ -17.20M | -2.59 | -17.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
REGENXBIO News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/08/2021 | 16:17 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting.. |
| 3/29/2021 | 13:28 | Edgar (US Regulatory) | Sec Staff Action/letter (sec Staff) |
| 3/01/2021 | 17:27 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 3/01/2021 | 17:06 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) |
| 3/01/2021 | 16:16 | Edgar (US Regulatory) | Annual Report (10-k) |
| 3/01/2021 | 16:11 | Seeking Alpha | Regenxbio EPS misses by $1.13, misses on revenue |
| 3/01/2021 | 16:07 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGNX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 34.86 | 35.37 | 33.82 | 34.74 | 329,431 | -0.76 | -2.18% |
| 1 Month | 40.88 | 42.44 | 32.18 | 36.73 | 414,497 | -6.78 | -16.59% |
| 3 Months | 48.34 | 49.63 | 32.18 | 40.92 | 403,725 | -14.24 | -29.46% |
| 6 Months | 29.22 | 50.26 | 26.40 | 40.50 | 444,473 | 4.88 | 16.7% |
| 1 Year | 33.60 | 50.26 | 25.925 | 37.89 | 400,221 | 0.50 | 1.49% |
| 3 Years | 35.10 | 85.10 | 20.03 | 46.68 | 492,184 | -1.00 | -2.85% |
| 5 Years | 11.53 | 85.10 | 7.0701 | 40.61 | 399,691 | 22.57 | 195.75% |
REGENXBIO Description
| Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). |
